Brief: Provectus Biopharmaceuticals To Not Undertake Reverse Split Of Outstanding, Authorized Equities
12/12/2022 13:30
Dec 12 (Reuters) - Provectus Biopharmaceuticals Inc
PVCT.PK :
* PROVECTUS BIOPHARMACEUTICALS ANNOUNCES DECISION TO NOT
UNDERTAKE
REVERSE SPLIT OF OUTSTANDING AND AUTHORIZED EQUITIES IN 2022;
EXPECTS TO SEEK SAME STOCKHOLDER APPROVAL AGAIN IN 2023
Source text for Eikon: ID:nGNX2VvYVQ
Further company coverage: PVCT.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Provectus Biopharmaceuticals
See all newsBrief: Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
RCS - VisiRose - VisiRose Introduces Therapy for Eye Infections
RCS - FINOS - FINOS Welcomes Seven Financial Leaders
Brief: Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting